17-N-Allylamino-17-demethoxygeldanamycin
From Wikipedia, the free encyclopedia
| 17-N-Allylamino-17-demethoxygeldanamycin | |
|---|---|
 |
|
| IUPAC name | [(3S,5S,6R,7S,8E,10R,11S,12E,14E)-21- (allylamino)-6-hydroxy-5,11-dimethoxy-3, 7,9,15-tetramethyl-16,20,22-trioxo-17- azabicyclo[16.3.1]docosa-8,12,14,18,21- pentaen-10-yl] carbamate |
| Identifiers | |
| CAS number | [75747-14-7] |
| PubChem | |
| SMILES | CC1CC(C(C(C=C(C(C(C=CC=C(C(=O)NC2=CC (=O)C(=C(C1)C2=O)NCC=C)C)OC)OC(=O)N)C)C)O)OC |
| Properties | |
| Molecular formula | C31H43N3O8 |
| Molar mass | 585.689 g/mol |
| Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) Infobox disclaimer and references |
|
17-N-Allylamino-17-demethoxygeldanamycin is a substance that is being studied in the treatment of cancer, specific young patients with certain types of leukemia or solid tumors, especially kidney tumors. As of June 2005, 17-N-allylamino-17-demethoxygeldanamycin is undergoing Phase 1 and Phase 2 clinical trials. It belongs to the family of drugs called antitumor antibiotics.
[edit] References
 |
This article does not cite any references or sources. (September 2007) Please help improve this article by adding citations to reliable sources. Unverifiable material may be challenged and removed. |
[edit] External links
- Phase 1 trial
- Another Phase 1 trial
- National Cancer Institutie Bulletin on Phase 2 trials against Von Hippel-Lindau disease
- Safety sheet for 17AAG
 |
This antibiotic-related article is a stub. You can help Wikipedia by expanding it. |
 |
This article about an organic compound is a stub. You can help Wikipedia by expanding it. |
